Editas Medicine (EDIT) Advancing Gene Editing Amid Struggles
Editas Medicine, Inc. (NASDAQ: EDIT) is a clinical-stage company specializing in genome editing, with a focus on developing transformative treatments for serious diseases. The company’s technology is based on CRISPR (clustered, regularly interspaced short palindromic repeats) and its associated protein, Cas9, enabling precise DNA editing. Editas’ stock proprietary platform uses CRISPR/Cas9 and CRISPR/Cas12a systems, positioning […]
Editas Medicine (EDIT) Advancing Gene Editing Amid Struggles Read More »